This week, the FDA will decide whether to approve Vertex Pharmaceuticals' non-opioid painkiller. Vertex believes pain could ...
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...
The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback